Expression of recombinant antibodies A Frenzel, M Hust, T Schirrmann Frontiers in immunology 4, 217, 2013 | 445 | 2013 |
Phage display-derived human antibodies in clinical development and therapy A Frenzel, T Schirrmann, M Hust MAbs 8 (7), 1177-1194, 2016 | 348 | 2016 |
Prevention of allograft rejection by use of regulatory T cells with an MHC‐specific chimeric antigen receptor F Noyan, K Zimmermann, M Hardtke‐Wolenski, A Knoefel, E Schulde, ... American Journal of Transplantation 17 (4), 917-930, 2017 | 269 | 2017 |
High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells V Jäger, K Büssow, A Wagner, S Weber, M Hust, A Frenzel, T Schirrmann BMC biotechnology 13 (52), 1-20, 2013 | 259 | 2013 |
Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection N Sherina, A Piralla, L Du, H Wan, M Kumagai-Braesch, J Andréll, ... Med 2 (3), 281-295. e4, 2021 | 210 | 2021 |
Single chain Fab (scFab) fragment M Hust, T Jostock, C Menzel, B Voedisch, A Mohr, M Brenneis, MI Kirsch, ... BMC biotechnology 7 (1), 14, 2007 | 181 | 2007 |
Mating antibody phage display with proteomics M Hust, S Dübel Trends in biotechnology 22 (1), 8-14, 2004 | 176 | 2004 |
A human scFv antibody generation pipeline for proteome research M Hust, T Meyer, B Voedisch, T Rülker, H Thie, A El-Ghezal, MI Kirsch, ... Journal of biotechnology 152 (4), 159-170, 2011 | 174 | 2011 |
Phage display for the generation of antibodies for proteome research, diagnostics and therapy T Schirrmann, T Meyer, M Schütte, A Frenzel, M Hust Molecules 16 (1), 412-426, 2011 | 174 | 2011 |
Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes M Tenspolde, K Zimmermann, LC Weber, M Hapke, M Lieber, J Dywicki, ... Journal of autoimmunity 103, 102289, 2019 | 152 | 2019 |
Encapsulation of proteins in hydrogel carrier systems for controlled drug delivery: Influence of network structure and drug size on release rate A Bertz, S Wöhl-Bruhn, S Miethe, B Tiersch, J Koetz, M Hust, H Bunjes, ... Journal of biotechnology 163 (2), 243-249, 2013 | 143 | 2013 |
Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant F Zuo, H Abolhassani, L Du, A Piralla, F Bertoglio, L de Campos-Mata, ... Nature Communications 13 (1), 1-8, 2022 | 139 | 2022 |
On the influence of vector design on antibody phage display G Soltes, M Hust, KKY Ng, A Bansal, J Field, DIH Stewart, S Dübel, S Cha, ... Journal of biotechnology 127 (4), 626-637, 2007 | 132 | 2007 |
Generating recombinant antibodies to the complete human proteome S Dübel, O Stoevesandt, MJ Taussig, M Hust Trends in biotechnology 28 (7), 333-339, 2010 | 130 | 2010 |
Generation and analysis of the improved human HAL9/10 antibody phage display libraries J Kügler, S Wilke, D Meier, F Tomszak, A Frenzel, T Schirrmann, S Dübel, ... BMC biotechnology 15 (1), 10, 2015 | 129 | 2015 |
Phage display derived therapeutic antibodies H Thie, T Meyer, T Schirrmann, M Hust, S Dubel Current pharmaceutical biotechnology 9 (6), 439-446, 2008 | 123 | 2008 |
Production systems for recombinant antibodies T Schirrmann, L Al-Halabi, S Dubel, M Hust Front Biosci 13 (13), 4576-94, 2008 | 122 | 2008 |
High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen … T Pelat, M Hust, E Laffly, F Condemine, C Bottex, D Vidal, MP Lefranc, ... Antimicrobial agents and chemotherapy 51 (8), 2758-2764, 2007 | 122 | 2007 |
Designing human antibodies by phage display A Frenzel, J Kügler, S Helmsing, D Meier, T Schirrmann, M Hust, S Dübel Transfusion Medicine and Hemotherapy 44 (5), 312-318, 2017 | 111 | 2017 |
The influence of antibody fragment format on phage display based affinity maturation of IgG M Steinwand, P Droste, A Frenzel, M Hust, S Dübel, T Schirrmann MAbs 6 (1), 204-218, 2014 | 102 | 2014 |